Quotient

JERSEY, Channel Islands, June 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient's MosaiQ platform.

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

JERSEY, Channel Islands, May 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.

Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates

New York Blood Center, Inc. and Centro de Transfusiones de la Comunidad de Madrid join MosaiQ's Innovator's Circle in partnership to improve patient care and laboratory efficiencies New York Blood Center, Inc. and Centro de Transfusiones de la Comunidad de Madrid join MosaiQ's Innovator's Circle in partnership to improve patient care and laboratory efficiencies

Quotient Limited Further Strengthens Scientific and Medical Synergies with the Expansion of the MosaiQ Innovator's Circle

The Extended Immunohematology microarray provides labs with comprehensive characterization, simplified workflow, and high throughput—all on a single multimodal multiplexing platform The Extended Immunohematology microarray provides labs with comprehensive characterization, simplified workflow, and high throughput—all on a single multimodal multiplexing platform

Quotient Limited Announces Receipt of CE Mark for the Extended Immunohematology Microarray

Quotient Limited (QTNT) CEO Manuel Mendez on Q3 2022 Results - Earnings Call Transcript

Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates

JERSEY, Channel Islands, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2022 key financial results and furnished an update on recent business developments.

Quotient Limited Reports Third Quarter Fiscal 2022 Results and Provides Business Update

Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development of NXP-001, which the latter has licensed from the former. Oxilio in turn is working with Quotient (NASDAQ:QTNT) Sciences, a drug development and manufacturing accelerator.

Nuformix hails progress partner is making with reformulated anti-sickness drug

JERSEY, Channel Islands, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. As part of the conference, the Company will be conducting a fireside chat on Thursday, February 17, 2022 at 8:00am ET.

Quotient Limited to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

JERSEY, Channel Islands, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today announced its attendance for the first time to the Arab Health and Medlab Middle East Conference in Dubai, United Arab Emirates. Medlab Middle East 2022, a co-located event with Arab Health, hosted its 21st edition of the congress, the region's only multi-disciplinary congress for the healthcare and laboratory industries.

Quotient Limited Provides MosaiQ Regulatory & Commercial Update

JERSEY, Channel Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2021 will be released before market open on Tuesday, February 8, 2022.

Quotient Limited to Report Third Quarter Fiscal Year 2022 Financial Results and Host Conference Call

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

JERSEY, Channel Islands, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today provided a Scientific Advisory Board and Research Program update. Quotient's Senior Management and Research and Development teams gathered with eight Transfusion Medicine KOLs from the US and Europe to highlight recent advances and future applications of the MosaiQ system. The Scientific and Medical Affairs Office has launched two new programs, the Innovator's Circle and an Investigator Initiated Research Program that will engage multiple global sites. Both are designed to foster developmental excellence in clinical diagnostics supported by independent and collaborative research to demonstrate the operational, scientific, and clinical value of MosaiQ's innovative technology.

Quotient Limited Launches Scientific Advisory Board and Research Programs

Quotient (QTNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Quotient (QTNT) Upgraded to Buy: Here's What You Should Know

Lazydays

Motorcar Parts of America

OptiNose

Sunopta

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

Quotient (QTNT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Quotient (QTNT) Could Find Support Soon, Here's Why You Should Buy the Stock Now

JERSEY, Channel Islands, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the company received feedback from the European notified body on the Expanded Immunohematology (IH) submission. The Company is pleased with the feedback and expects to submit a response to the questions in the next couple of weeks.

Quotient Limited Provides Update on MosaiQ Expanded Immunohematology Microarray CE Marking Progress

Investors need to pay close attention to Quotient Limited (QTNT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Quotient Limited (QTNT) Stock?

JERSEY, Channel Islands, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report on Form 10-Q.

Quotient Limited Provides Second Quarter Fiscal 2022 Results

JERSEY, Channel Islands, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the management team will present at the Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 8:40am GMT (3:40am ET).

Quotient Limited to Participate in the Jefferies London Healthcare Conference

Quotient Limited (QTNT) CEO Manuel Méndez on Q2 2022 Results - Earnings Call Transcript

JERSEY, Channel Islands, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has received unanimous consents from the holders of its 12% Senior Secured Notes (the Notes) to certain amendments to the Indenture governing the Notes (the Indenture Amendments).

Quotient Limited Announces receipt of Note Holders Consents to Indenture Amendments That Extend Maturity, Defer Principal Payments on 12% Senior Secured Notes

JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end.

Quotient Limited Announces Appointment of Chief Financial Officer

JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally.

Quotient Limited Announces Appointment of Chief Commercial Officer

Investors need to pay close attention to Quotient (QTNT) stock based on the movements in the options market lately.

News for Quotient Stock (QTNT)